Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Dose-Response Relationships of Acid-Inhibitory Effect and Efficacy of TAK-438 (20 mg, 40 mg) in Patients with PPI-Resistant Erosive Esophagitis.

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Dose-Response Relationships of Acid-Inhibitory Effect and Efficacy of TAK-438 (20 mg, 40 mg) in Patients with PPI-Resistant Erosive Esophagitis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vonoprazan (Primary)
  • Indications Reflux oesophagitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda

Most Recent Events

  • 24 May 2016 Results presented at the Digestive Disease Week 2016
  • 07 Feb 2014 According to the ClinicalTrials.gov record, status changed to completed.
  • 03 Jul 2012 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top